20.02.2025 20:53:59
|
Bio-Techne Expands RNAscope Probes For Human And Mouse Transcriptome In Spatial Biology
(RTTNews) - Bio-Techne (TECH), a US-based biotechnology company Thursday has introduced an expanded range of human and mouse RNAscope in situ hybridization probes to support spatial biology research and the development of next-generation therapeutics and diagnostics. Branded under Advanced Cell Diagnostics, the RNAscope portfolio now features over 70,000 unique probes spanning more than 450 species, offering exceptional spatial precision with industry-leading sensitivity and specificity.
As the most widely referenced spatial biology technology, RNAscope offers an unparalleled single-cell view of disease pathology and therapeutic response across various conditions.
Supported by the RNAscope probe guarantee, this expanded probe menu helps researchers accelerate RNA biomarker validation from single-cell genomics and spatial discovery programs. Available on bio-techne.com, customers can easily pair RNAscope probes with R&D Systems antibodies to better analyze cell phenotypes and functional states.
With preconfigured manual and automated options, including support for the Lunaphore COMET system, researchers can effortlessly progress RNA and multiomic biomarkers from initial discovery to translational research and clinical assay development while ensuring design consistency with RNAscope probes.
TECH is currently trading at $66.07 or 0.42% higher on the Nasdaq Global Select Market.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
20.02.25 |
S&P 500-Titel Bio-Techne-Aktie: So viel Verlust hätte ein Bio-Techne-Investment von vor 3 Jahren eingebracht (finanzen.at) | |
13.02.25 |
S&P 500-Papier Bio-Techne-Aktie: Wäre eine Bio-Techne-Kapitalanlage von vor einem Jahr lukrativ gewesen? (finanzen.at) | |
10.02.25 |
Börse New York: S&P 500 liegt schlussendlich im Plus (finanzen.at) | |
10.02.25 |
Starker Wochentag in New York: S&P 500 verbucht Gewinne (finanzen.at) | |
10.02.25 |
Aufschläge in New York: Börsianer lassen S&P 500 am Montagmittag steigen (finanzen.at) | |
10.02.25 |
Handel in New York: S&P 500 bewegt sich zum Start im Plus (finanzen.at) | |
06.02.25 |
S&P 500-Titel Bio-Techne-Aktie: So viel Gewinn hätte ein Bio-Techne-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
05.02.25 |
Verluste in New York: S&P 500 zum Handelsstart in Rot (finanzen.at) |
Analysen zu Bio-Techne Corpmehr Analysen
Aktien in diesem Artikel
Bio-Techne Corp | 62,00 | -0,80% |
|